Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March
Pacira BioSciences (Nasdaq: PCRX), a leader in non-opioid pain therapies, has announced its participation in two major healthcare conferences in March 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pacira BioSciences (Nasdaq: PCRX), a leader in non-opioid pain therapies, has announced its participation in two major healthcare conferences in March 2025. The company will engage in analyst-led fireside chats at:
- The Raymond James 46th Annual Institutional Investors Conference on March 5th at 10:25AM ET
- The Barclays 27th Annual Global Healthcare Conference on March 12th at 8:00AM ET
Both events will be accessible via live audio on the company's website investor.pacira.com under the 'Events' section. Webcasts will remain available for replay for two weeks following each event.
Details
News Market Reaction – PCRX
The recorded move for PCRX in the trading session of this news was +1.51%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARSIPPANY, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:
- Raymond James 46th Annual Institutional Investors Conference on Wednesday, March 5th at 10:25AM ET.
- Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12th at 8:00AM ET.
Live audio of the events can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcasts will also be available for two weeks following the events.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.